Drugmaker Pfizer said Thursday that it is working on a promising treatment for coronavirus, as well as vaccine.
The drugmaker said preclinical studies showed that an unspecified compound that was originally used to treat SARS — a different coronavirus — has shown potential in battling the dangerous illness.
Pfizer research chief Mikael Dolsten said the drug blocks COVID-19 from replicating, slowing the spread in mild or moderate cases, the Wall Street Journal reported.
The company said it will conduct additional preclinical studies and plans to launch human trials in the summer.
Pfizer also said it will support studies to determine whether its existing medicines, including its rheumatoid arthritis drug Xeljanz, may provide help for those suffering from respiratory problems from the virus.
The drugmaker has also finalized a plan to work with German company BioNTech to develop a vaccine, which could be tested in human trials as early as the end of the month. The companies hope to produce millions of vaccines by the end of 2020.
“I feel confident that we will win, battle by battle, to turn around this viral war against our society,” Dolsten told the Journal.
With Post wires
Source: Read Full Article